Relapses in patients with giant cell arteritis: Prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients

Medicine (United States)

Volumn 93, Issue 5, 2014, Pages 194-201

  Alba, Marco A ^a   García Martínez, Ana ^a   Prieto González, Sergio ^a   Tavera Bahillo, Itziar ^a   Corbera Bellalta, Marc ^a   Planas Rigol, Ester ^a   Espígol Frigolé, Georgina ^a   Butjosa, Montserrat ^a   Hernández Rodríguez, José ^a   Cid, Maria C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; HAPTOGLOBIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; GLUCOCORTICOID;

ADULT; AGED; ANOREXIA; ARTICLE; BLINDNESS; CATARACT; CLAUDICATION; CLINICAL FEATURE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; CUSHING DISEASE; DIABETES MELLITUS; DIPLOPIA; DRUG PULSE THERAPY; FACE PAIN; FEMALE; FEVER; FOLLOW UP; GIANT CELL ARTERITIS; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; JAW DISEASE; LONGITUDINAL STUDY; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; RELAPSE; RHEUMATIC POLYMYALGIA; SCALP TENDERNESS; SKIN DISEASE; SYSTEMIC DISEASE; TRANSIENT ISCHEMIC ATTACK; TRANSITIONAL BLINDNESS; WEIGHT REDUCTION; DISEASE COURSE; DOSE RESPONSE; DRUG TOLERANCE; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT ACUITY; PREVALENCE; SPAIN; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FEMALE; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OSTEOPOROSIS; PATIENT ACUITY; POLYMYALGIA RHEUMATICA; PREDNISONE; PREVALENCE; RECURRENCE; SPAIN;

EID: 84907935311     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000033     Document Type: Article

References (28)

1. Aiello PD, Trautmann JC, McPhee TJ, et al. Visual prognosis in giant cell arteritis. Ophthalmology. 1993;100:550-555.
2. Alba MA, Espigol-Frigole G, Butjosa M, et al. Treatment of large vessel vasculitis. Curr Immunol Rev. 2011;7:435-442.
3. Andersson R, Malmvall BE, Bengtsson BA. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand. 1986;220:465-469.
4. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Technical Report Series. Vol. 843. World Health Organization; 1994: 1-129.
5. Bongartz T, Matteson EL. Large-vessel involvement in giant cell arteritis. Curr Opin Rheumatol. 2006;18:10-17.
6. Ciccia F, Alessandro R, Rizzo A, et al. IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis. Ann Rheum Dis. 2013;72:258-264.
7. Cid MC, Font C, Oristrell J, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum. 1998;41:26-32.
8. Cid MC, Garcia-Martinez A, Lozano E, et al. Five clinical conundrums in the management of giant cell arteritis. Rheum Dis Clin North Am. 2007;33:819-834, vii.
9. Cid MC, Hoffman MP, Hernandez-Rodriguez J, et al. Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis. Rheumatology (Oxford). 2006;45:1356-1363.
10. Coll-Vinent B, Vilardell C, Font C, et al. Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule-1 (sICAM-1) concentrations and disease activity. Ann Rheum Dis. 1999;58:189-192.
11. Espigol-Frigole G, Corbera-Bellalta M, Planas-Rigol E, et al. Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. Ann Rheum Dis. 2013;72:1481-1487.
12. Garcia-Martinez A, Hernandez-Rodriguez J, Espigol-Frigole G, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res (Hoboken). 2010;62:835-841.
13. Hernandez-Rodriguez J, Cid MC, Lopez-Soto A, et al. Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med. 2009;169:1839-1850.
14. Hernandez-Rodriguez J, Garcia-Martinez A, Casademont J, et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum. 2002;47:29-35.
15. Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46:1309-1318.
16. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621-630.
17. Hunder GG, Sheps SG, Allen GL, et al. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med. 1975;82:613-618.
18. Jennette JC, Falk RJ, Bacon PA, et al. Revised international Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1-11.
19. Jover JA, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106-114.
20. Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis. 1989;48:658-661.
21. Kyle V, Hazleman BL. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis. 1993;52:847-850.
22. Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data metaanalysis. Arthritis Rheum. 2007;56:2789-2797.
23. Martinez-Lado L, Calvino-Diaz C, Pineiro A, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore). 2011;90:186-193.
24. Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54:3310-3318.
25. Nesher G, Nesher R, Mates M, et al. Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. Clin Exp Rheumatol. 2008;26:S30-S34.
26. Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49:703-708.
27. Salvarani C, Pipitone N, Versari A, et al. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol. 2012;8:509-521.
28. Visvanathan S, Rahman MU, Hoffman GS, et al. Tissue and serum markers of inflammation during the follow-up of patients with giantcell arteritis-a prospective longitudinal study. Rheumatology (Oxford). 2011;50:2061-2070.